Pharmacokinetics and Dose Proportionality of Loratadine

The dose proportionality and pharmacokinetics of loratadine, a new nonsedating antihistamine, were studied in 12 normal volunteers. In a three‐way cross‐over, each volunteer received a single 10‐, 20‐, or 40‐mg loratadine capsule. Blood was collected up to 96 hours after dosing. Plasma loratadine concentrations were determined by radioimmunoassay (RIA), and those of a minor, but active metabolite, descarboethoxyloratadine, by high performance liquid chromatography (HPLC). Concentrations in the disposition phase were fitted to a biexponential equation for pharmacokinetic analysis. For dose proportionality, AUC‐ and C max ‐dose relationships were evaluated by linear regression. Also, pharmacokinetic parameters and dose‐adjusted AUCs were compared by analysis of variance. Loratadine was rapidly absorbed, reaching C max values (4.7, 10.8, and 26.1 ng/mL) at 1.5, 1.0 and 1.2 hours for the 10‐, 20‐, and 40‐mg doses, respectively. The loratadine t 1/2β ranged from 7.8 to 11.0 hours. Descarboethoxyloratadine reached C max values (4.0, 9.9, and 16.0 ng/mL) at 3.7, 1.5, and 2.0 hours for the 10‐, 20‐, and 40‐mg doses, respectively. Its t 1/2β ranged from 17 to 24 hours. For both compounds, AUC‐ and C max ‐dose relationships were linear and there were no differences in the t 1/2β , CL/F, or dose‐adjusted AUC values among the treatments. Loratadine and descarboethoxyloratadine plasma concentrations and pharmacokinetics were not dose dependent.